Literature DB >> 11803488

MYOC mutation frequency in primary open-angle glaucoma patients from Western Switzerland.

A Mataftsi1, F Achache, E Héon, A Mermoud, P Cousin, G Metthez, D F Schorderet, F L Munier.   

Abstract

PURPOSE: To determine MYOC gene mutation frequency in patients with primary open-angle glaucoma (POAG) from Western Switzerland.
METHODS: A total of 117 unselected index patients with primary open-angle glaucoma were submitted to a full eye examination. DNA was extracted from blood and PCR amplicons of MYOC exon 3 were screened for mutations by single-strand conformation polymorphism (SSCP) analysis. Abnormal conformers were analyzed both by direct bidirectional sequencing and by enzymatic mutation detection (EMD) assay.
RESULTS: Ten occurrences of four different sequence changes were detected, including: 1) five times the same disease-causing mutation (Q368X) in five unrelated POAG patients and 2) three distinct polymorphisms in five patients. The patients carrying an MYOC mutant allele were characterized by a broad clinical variability in terms of age of onset (34-77 years) and highest intraocular pressure (IOP) values (23-47 mmHg).
CONCLUSIONS: A pathogenic MYOC mutation (Q368X) was identified in 4.27% (5/117) of the studied population from Western Switzerland, which corresponds to the highest frequency yet reported for this mutation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11803488     DOI: 10.1076/opge.22.4.225.2218

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  2 in total

1.  Low prevalence of MYOC mutations in UK primary open-angle glaucoma patients limits the utility of genetic testing.

Authors:  Micheala A Aldred; Laura Baumber; Alison Hill; Edward C Schwalbe; Kai Goh; Wojciech Karwatowski; Richard C Trembath
Journal:  Hum Genet       Date:  2004-08-25       Impact factor: 4.132

Review 2.  Myocilin polymorphisms and primary open-angle glaucoma: a systematic review and meta-analysis.

Authors:  Jin-Wei Cheng; Shi-Wei Cheng; Xiao-Ye Ma; Ji-Ping Cai; You Li; Guo-Cai Lu; Rui-Li Wei
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.